Document Detail

Improvement in long-term prognosis of elderly patients with acute myocardial infarction after the introduction of intravenous thrombolytic therapy.
MedLine Citation:
PMID:  9862099     Owner:  NLM     Status:  MEDLINE    
Survival rate from a "thrombolytic" period of 351 patients above 66 years of age with acute myocardial infarction (AMI) was compared with that of 289 patients from a "prethrombolytic" period. The two groups were comparable regarding sex, age, previous AMI, cerebrovascular events, morbidity and mortality during admission. Survival rates after four years were 45.0% in the "thrombolytic" group and 38.4% in the "prethrombolytic" group (p = 0.047, log rank test). Using the Cox proportional hazard analysis, thrombolytic therapy was shown to be an independent prognostic predictor in "the thrombolytic population" with a relative risk of death from day 30 to end of follow-up of 0.4 (95% confidence interval 0.2-0.8). No interaction was found between age and thrombolysis. Although only one-fifth of the patients with AMI were eligible for thrombolysis, this treatment may have contributed to the improved long-term survival.
J K Madsen; F Pedersen; H Nielsen; G V Jensen; J F Hansen
Related Documents :
18378519 - Treatment of hypertension in patients 80 years of age or older.
15019339 - Surgery for trichiasis by ophthalmologists versus integrated eye care workers: a random...
22354609 - Reason for revision influences early patient outcomes after aseptic knee revision.
21067459 - Adherence and persistence of single-pill arb/ccb combination therapy compared to multip...
22027509 - A case of textile dermatitis due to disperse blue on the surgical wound.
2323599 - Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study.
8695159 - Adverse effects after radical external beam radiotherapy of localized prostatic adenoca...
15612959 - Role of arterial blood gas abnormalities in oedema formation in copd.
6122099 - Effect of gl enzyme (a highly purified form of hyaluronidase) on mortality after myocar...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Scandinavian cardiovascular journal : SCJ     Volume:  32     ISSN:  1401-7431     ISO Abbreviation:  Scand. Cardiovasc. J.     Publication Date:  1998  
Date Detail:
Created Date:  1999-02-25     Completed Date:  1999-02-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9708377     Medline TA:  Scand Cardiovasc J     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  365-70     Citation Subset:  IM    
Department of Cardiology, Hvidovre Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Fibrinolytic Agents / administration & dosage,  therapeutic use
Follow-Up Studies
Myocardial Infarction / drug therapy*,  mortality*
Proportional Hazards Models
Streptokinase / administration & dosage,  therapeutic use
Survival Rate
Thrombolytic Therapy*
Time Factors
Tissue Plasminogen Activator / administration & dosage,  therapeutic use
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure...
Next Document:  Unusual course of right atrial myxoma, masked by acute abdominal pain, and complicated by pulmonary ...